Guido Würth
Head of Corporate Development & Radiopharma Medical & Health; Sales; Operations Affibody AB
Guido Wuerth joined Affibody AB in 2021 and leads Corporate Development for the company’s radiopharmaceutical portfolio, overseeing development strategy, asset positioning, and partnering activities. Previously, he held senior leadership roles at MorphoSys, serving as Global Program Head and contributing to the U.S. approval of tafasitamab (MONJUVI®) and multiple out-licensing transactions. Earlier, he led Global Clinical Operations at Sandoz and served as Global Program Medical Director for the etanercept biosimilar Erelzi®, with extensive regulatory experience. Guido has also held senior positions at Baxter, Antisense Pharma, and Schwarz Pharma (now UCB). He is a board-certified urologist and holds an MD from the University of Cologne, Germany.
Seminars
- Characterizing mechanisms of renal and hepatic injury associated with alpha-emitting radioligand therapies
- Evaluating clinical and molecular strategies to reduce off-target organ exposure and cumulative toxicity
- Guiding dosing, scheduling, and patient monitoring to enable safer clinical application of novel alpha emitters
